Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ICaPath
AddedFeb 18, 2024
UpdatedJun 18, 2026
ICaPath

ICaPath

Seed

ICaPath, a Morgantown-based biotech startup, specializes in nanoparticle immunotherapy and diagnostics.

HQ
Morgantown, WV, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

ICaPath, founded in Morgantown, West Virginia, is a biotech startup focused on advancing nanoparticle immunotherapy and diagnostics. The company's core mission is to pioneer innovative therapies and diagnostic tools to improve patient outcomes. ICaPath aims to address critical healthcare needs through its cutting-edge technology pipeline, which includes non-specific immunotherapies designed to target a range of diseases. Their market focus spans both therapeutic and diagnostic applications, aiming to revolutionize the biotech landscape.

Notable figures associated with ICaPath include leading scientists and biotech experts, though specific names are not provided. The company has garnered attention for its innovative approach to immunotherapy, achieving significant milestones in preclinical development. ICaPath's impact is marked by its potential to transform treatment protocols and diagnostic accuracy, positioning it as a promising player in the biotech industry.

ICaPath - Similar Companies

Nanopath logo

Nanopath

nanopathdx.com

Nantkwest logo

Nantkwest

RootPath Genomics logo

RootPath Genomics

rootpath.com

Pathware logo

Pathware

pathware.com

PathoGene logo

PathoGene

Instapath Inc. logo

Instapath Inc.

instapathbio.com

Ionpath logo

Ionpath

Inimmune logo

Inimmune

inimmune.com

impathi. logo

impathi.

Ionica Sciences logo

Ionica Sciences

Endpoint Health logo

Endpoint Health

ImmuneTarget logo

ImmuneTarget

RoboPath logo

RoboPath

robopath.io

Gopath Laboratories logo

Gopath Laboratories

ImmunoProfile logo

ImmunoProfile

immunoprofile.com

ICaPath - Quick Facts

Who are ICaPath's competitors?

Companies similar to ICaPath include Nanopath, Nantkwest, RootPath Genomics and Pathware.

When was ICaPath founded?

ICaPath was founded in 2019.

Where is ICaPath's headquarters located?

ICaPath's headquarters is located in Morgantown, WV, US.

When was ICaPath's last funding round?

ICaPath's most recent funding round was for $650k (USD) in September 2022.

How much has ICaPath raised to-date?

As of Sep 15, 2022, ICaPath has raised a total of $650k (USD).

How many employees does ICaPath have?

ICaPath has 5 employees as of Feb 5, 2024.

ICaPath - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Nanotechnology
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Diagnostics
  • Immunotherapy
Tags
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software